Answers are grounded in this paper and cite their sources.
Prospective cohort study identifies FGF21 as a predictor for fragility fractures in type 2 diabetes, highlighting its clinical significance.
Fibroblast growth factor 21 (FGF21) levels are elevated with type 2 diabetes mellitus (T2D). This study aimed to elucidate whether FGF21 is a predictor for fragility fractures and to construct a predictive model using FGF21 as a risk factor to predict fractures in T2D. This prospective cohort study enrolled 371 individuals with high atherosclerotic risk, of whom 60.4% had T2D. FGF21 was measured at enrollment. The first incident fragility fractures were recorded. Individuals with T2D had a higher risk of major fractures (SHR 3.64, 95% CI 1.24–10.71) and tended toward a higher risk of any fractures (SHR 2.50, 95% CI 0.99–6.33). FGF21 was an independent risk factor for fractures in individuals with T2D. A predictive model comprising age, gender, 10-year probability of major osteoporotic fractures (FRAX-M) based on body mass index (BMI), FGF21, and aspartate transaminase (AST) demonstrated an AuROC of 0.84 and sensitivity and specificity of 84.2% and 74.5%, respectively, to predict fractures in T2D. The predictive risk score with the threshold of 103, which had an AuROC of 0.79, a sensitivity of 84.2%, and a specificity of 75.5%, was proposed for clinical application. In conclusion, FGF21 was a novel risk factor for fragility fractures in T2D. A predictive model and predictive risk score using age, gender, BMI-based FRAX-M, AST, and FGF21 showed high performance for predicting fractures in T2D. This predictive model may benefit clinical practice after further external validation.
No takes yet. Share an insight, caveat, or question.
Phimphilai et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: